다양한 만성 통증 질환에서 5% 리도카인 패치의 유용성 연구 = An Open-Label Trial of the 5% Lidocaine Patches for the Treatment of Chronic Pain

참고문헌 (Reference)

1 심우석, "대상포진 및 대상포진후신경통 환자의 치료" 대한통증학회 21 (21): 93-105, 2008

2 Galer BS, "Use of the lidocaine patch 5% in reducing intensity of various pain qualities reported by patients with low-back pain" 20 : 5-12, 2004

3 Hines R, "Use of lidocaine patch 5% for chronic low back pain: a report of four cases" 3 : 361-365, 2002

4 Devers A, "Topical lidocaine patch relieves a variety of neuropathic pain conditions: an open-label study" 16 : 205-208, 2000

5 Galer BS, "Topical lidocaine patch 5% may target a novel underlying pain mechanism in osteoarthritis" 20 : 1455-1458, 2004

6 김택훈, "The effect of TNF-α and INF-γ on the telomerase activity of cultured human keratinocyte" 대한피부과학회 19 (19): 1-1, 2007

7 Mao J, "Systemic lidocaine for neuropathic pain relief" 87 : 7-17, 2000

8 Campbell BJ, "Systemic absorption of topical lidocaine in normal volunteers, patients with post-herpetic neuralgia, and patients with acute herpes zoster" 91 : 1343-1350, 2002

9 Davies PS, "Review of lidocaine patch 5% studies in the treatment of postherpetic neuralgia" 64 : 937-947, 2004

10 Verhaak PF, "Prevalence of chronic benign pain disorder among adults: a review of the literature" 77 : 231-239, 1998

11 Dworkin RH, "Pharmacologic management of neuropathic pain: evidence-based recommendations" 132 : 237-251, 2007

12 Gammaitoni AR, "Pharmacokinetics and safety of continuously applied lidocaine patches 5%" 59 : 2215-2220, 2002

13 Gimbel J, "Lidocaine patch treatment in patients with low back pain: results of an open-label, nonrandomized pilot study" 12 : 311-319, 2005

14 White WT, "Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain" 4 : 321-330, 2003

15 Fishbain DA, "Lidocaine 5% patch: an open-label naturalistic chronic pain treatment trial and prediction of response" 7 : 135-142, 2006

16 Baron R, "Efficacy and safety of combination therapy with 5% lidocaine medicated plaster and pregabalin in post- herpetic neuralgia and diabetic polyneuropathy" 25 : 1677-1687, 2009

17 Baron R, "Efficacy and safety of 5% lidocaine (lignocaine) medicated plaster in comparison with pregabalin in patients with postherpetic neuralgia and diabetic polyneuropathy: interim analysis from an open-label, two-stage adaptive, randomized, controlled trial" 29 : 231-241, 2009

18 Barbano RL, "Effectiveness, tolerability, and impact on quality of life of the 5% lidocaine patch in diabetic polyneuropathy" 61 : 914-918, 2004

19 Argoff CE, "Effectiveness of the lidocaine patch 5% on pain qualities in three chronic pain states: assessment with the neuropathic pain scale" 20 : 21-28, 2004

20 Saber AA, "Early experience with lidocaine patch for postoperative pain control after laparoscopic ventral hernia repair" 7 : 36-38, 2009

21 Zhang JM, "Decreasing sympathetic sprouting in pathologic sensory ganglia: a new mechanism for treating neuropathic pain using lidocaine" 109 : 143-149, 2004

22 Kivitz A, "Comparison of the effectiveness and tolerability of lidocaine patch 5% versus celecoxib for osteoarthritis-related knee pain: post hoc analysis of a 12 week, prospective, randomized, active-controlled, open-label, parallel-group trial in adults" 30 : 2366-2377, 2008

23 Zin CS, "An update on the pharmacological management of post-herpetic neuralgia and painful diabetic neuropathy" 22 : 417-442, 2008

24 Finnerup NB, "An evidence- based algorithm for the treatment of neuropathic pain" 9 : 36-36, 2007

25 Affaitati G, "A randomized, controlled study comparing a lidocaine patch, a placebo patch, and anesthetic injection for treatment of trigger points in patients with myofascial pain syndrome: evaluation of pain and somatic pain thresholds" 31 : 705-720, 2009